Trump victory elicits fears, some cheers around the globe

November 9, 2016

London, Nov 9: The world faces a starkly different America led by a President Donald Trump.trumpGlb

While the billionaire businessman's election was welcomed in some countries, others saw it as a big shock, as governments will now have to deal with a man who has cozied up to Vladimir Putin, told NATO allies they would have to pay for their own protection and vowed to make the Mexican government pay for a multibillion-dollar border wall.

Trump's win was particularly startling in Mexico, where his remarks calling Mexican immigrants criminals and 'rapists' were a deep insult to national pride. Financial analysts have predicted a Trump win would threaten billions of dollars in cross-border trade, and government officials say they have drawn up a contingency plan for such a scenario, though without releasing details.

"It's DEFCON 2," Mexican analyst Alejandro Hope said. "Probably something as close to a national emergency as Mexico has faced in many decades."

"It depends if he means what he says and if he can do what he claims he wants to do," Hope added. "A massive deportation campaign could really put some stress on Mexican border communities. A renegotiation of NAFTA could seriously hobble the Mexican economy. It could create a lot of uncertainty. ... Financial markets could suffer."

The Mexican peso, which has tracked the U.S. election closely, fell sharply to 20.45 to the dollar late Tuesday before recovering somewhat. The Bank of Mexico's interbank rate had stood at 18.42 at the end of the day's trading.

In Europe, NATO allies now wait to see if Trump follows through on suggestions that America will look at whether they have paid their proper share in considering whether to come to their defense.

Trump's rhetoric has challenged the strategic underpinning of the NATO alliance, rattling its leaders at a time when Russia has been increasingly aggressive.

German Defense Minister Ursula von der Leyen called the vote 'a big shock' and 'a vote against Washington, against the establishment.'

Von der Leyen said on German public Television Wednesday that while many questions remain open, "We Europeans obviously know that as partners in NATO, Donald Trump will naturally ask what 'are you achieving for the alliance,' but we will also ask 'what's your stand toward the alliance.'"

The French populist, anti-immigrant politician Marine Le Pen congratulated Trump even before the final results were known, tweeting her support to the "American people, free!"

Foreign Minister Jean-Marc Ayrault said France would work with the new president and that European politicians should heed the message from Trump votes. "There is a part of our electorate that feels ... 'abandoned,' including people who feel left behind by globalization," he said.

Trump's victory is being viewed with shock and revulsion in Ireland, a country close to the Clintons and fearful of Trump's campaign pledge to confront US companies using Ireland as a tax shelter.

The newspaper of record, the Irish Times, branded the New York businessman a 'misogynistic racist liar' who would fan instability overseas and intolerance at home.

Irish Times columnist Fintan O'Toole wrote Wednesday: "The republic of Washington, Jefferson, Lincoln and Roosevelt is now the United Hates of America."

"President Trump is the creation of the same demographic that gave Europe its far-right authoritarian movements with such disastrous consequences for the world," he wrote. "This does not mean that we are facing an American fascism. But it does mean that Trump will not be able to rule without stoking and manipulating fear."

British Prime Minister Theresa May issued a statement saying she looks forward to working with Trump and building on the two countries' longstanding 'special relationship.' Her predecessor, David Cameron, had been outspoken in his criticism of Trump during the primary campaign.

Nigel Farage, acting leader of the UK Independent Party, which played an important role convincing Britons to leave the European Union, told The Daily Telegraph that Trump's victory would bring a 'massive result' for Britain. A spokesman said Farage - who campaigned briefly with Trump- was flying to Washington Wednesday.

Russian President Vladimir Putin sent Trump a telegram Wednesday morning congratulating him on his victory.

Moscow has been unusually prominent in the race. Clinton's campaign and the Obama administration blamed Russian hackers for leaked emails from the Democratic National Committee and Clinton campaign staff. Trump, in turn, has made complimentary remarks about Putin; the ties some of his advisers and former campaign officials have to Russia have raised suspicions.

"We of course regard with satisfaction that the better candidate of the two presented to the American voters was victorious," said Vladimir Zhirinovsky, leader of Russia's nationalist Liberal Democratic party, according to the Interfax news agency.

In Asia, security issues and trade will top the agenda for the new administration, from North Korea and the South China Sea to the contentious and yet-unratified Trans-Pacific Partnership trade agreement.

Chinese state media and government-backed commentators had signaled Beijing's preference for a Trump win. Like Russia, China is seen as favoring Trump because he appears less willing to confront China's newly robust foreign policy, particularly in the South China Sea.

Clinton, by contrast, is disliked in Beijing for having steered the US 'pivot' to Asia aimed at strengthening US engagement with the region, particularly in the military sphere.

Scholar Mei Xinyu wrote in the Communist Party newspaper Global Times that China would find it easier to cope with a Trump presidency.

"Trump has always insisted on abandoning ideological division and minimizing the risks that unnecessary conflicts with other countries may bring to the U.S.," Mei wrote.

In Indonesia, the world's most populous Muslim country, social media was abuzz with speculation about whether Trump would follow through on campaign rhetoric calling for a ban on Muslims entering the United States. Some said they fear they would be prevented from visiting relatives and friends who live in America or traveling there as tourists.

News of Trump's widening lead hit hard in Cuba, which has spent the last two years negotiating normalization with the United States after more than 50 years of Cold War hostility, setting off a tourism boom. Trump has promised to roll back Obama's opening with Cuba unless President Raul Castro agrees to more political freedoms.

"If he reverses it, it hurts us," taxi driver Oriel Iglesias Garcia said. "You know tourism will go down."

In pubs, bars and restaurants in much of the world, people watched TV and took in the surprise news of Trump's victory.

At a pub in Sydney, Pamela Clark-Pearman, a 63-year-old Clinton supporter, sat nursing a beer.
"I never thought the Americans could be so stupid. I just think it's Brexit all over again,'' Clark-Pearman said, referring to the June 23 British vote to leave the European Union.

Serving the last drinks of the night at a Mexico City tavern where a half-dozen TVs were tuned to election news, bartender Angel Mendoza wondered what will happen to his 15 or so family members living in the United States, about half of whom are there illegally.

"They're not coming here," he said. "Their lives are already made there, but (now) with a certain fear."

Comments

ABD
 - 
Wednesday, 9 Nov 2016

When Authority / Power comes to the hands of unfit person, then wait for the Hour - Muhammad(Pbuh)

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
June 4,2020

Jun 4: A malaria drug President Donald Trump took to try to prevent COVID-19 proved ineffective for that in the first large, high-quality study to test it in people in close contact with someone with the disease.

Results published Wednesday by the New England Journal of Medicine show that hydroxychloroquine was no better than placebo pills at preventing illness from the coronavirus.

The drug did not seem to cause serious harm, though -- about 40% on it had side effects, mostly mild stomach problems.

 “We were disappointed. We would have liked for this to work,” said the study leader, Dr. David Boulware, an infectious disease specialist at the University of Minnesota.

“But our objective was to answer the question and to conduct a high-quality study,” because the evidence on the drug so far has been inconclusive, he said.

Hydroxychloroquine and a similar drug, chloroquine, have been the subject of much debate since Trump started promoting them in March.

Hydroxychloroquine has long been used for malaria, lupus, and rheumatoid arthritis, but no large studies have shown it or chloroquine to be safe or effective for much sicker patients with coronavirus, and some studies have suggested the drugs may do harm.

Trump took a two-week course of hydroxychloroquine, along with zinc and Vitamin D, after two staffers tested positive for COVID-19, and had no ill effects, according to results of his latest physical released by his doctor Wednesday.

Federal regulators have warned against hydroxychloroquine's use except in hospitals and formal studies because of the risk of side effects, especially heart rhythm problems.

Boulware's study involved 821 people in the United States and Canada living with someone diagnosed with COVID-19 or at high risk of getting it because of their job -- doctors, nurses, ambulance workers who had significant exposure to a sick patient while not wearing full protective gear.

They were randomly assigned to get either the nutrient folate as a placebo or hydroxychloroquine for five days, starting within four days of their exposure. Neither they nor others involved in the research knew who was getting which pills.

After 14 days in the study, 12 per cent on the drug developed COVID-19 symptoms versus 14 per cent in the placebo group, but the difference is so small it could have occurred by chance, Boulware said.

“There's basically no effect. It does not prevent infection,” he said of the drug. Even if it were to give some slim advantage, “we'd want a much larger effect” to justify its use and risk of side effects for preventing illness, he said.

Results were no different among a subgroup of participants who were taking zinc or vitamin C, which some people believe might help make hydroxychloroquine more effective or fight the coronavirus.

There are some big caveats: The study enrolled people through the Internet and social media, relying on them to report their own symptoms rather than having them tracked in a formal way by doctors.

Participants were not all tested for the coronavirus but were diagnosed as COVID-19 cases based on symptoms in many cases. And not all took their medicines as directed.

The results “are more provocative than definitive,” and the drug may yet have prevention benefits if tried sooner or in a different way, Dr. Myron Cohen of the University of North Carolina at Chapel Hill wrote in a commentary in the journal.

Others were glad to see a study that had a comparison group and good scientific methods after so many weaker reports on hydroxychloroquine.

“This fits with everything else we've seen so far which suggests that it's not beneficial," said Dr. Peter Bach, director of a health policy center at Memorial Sloan Kettering Cancer Center in New York.

This study was in younger relatively healthy people, but the results “would make me very discouraged about trying to use this in older people” who are most vulnerable to serious illness from the coronavirus, Bach said.

“If it does work, it doesn't work very well.” Dr. Dan Culver, a lung specialist at the Cleveland Clinic, said there's still a chance that giving the drug sooner than four days after someone's exposure to the virus may help prevent illness.

But the study “takes 'home run' off the table” as far as hopes for the drug, he said.

The study was mostly funded by David Baszucki, founder of Roblox, a California-based game software company, and other private donors and the Minnesota university.

Boulware also is leading a study testing hydroxychloroquine for treating COVID-19. The study is finished and results are being analyzed now.

On Tuesday, the journal Lancet posted an “expression of concern” about a study it published earlier this month of nearly 15,000 COVID-19 patients on the malaria drugs that tied their use to a higher risk of dying in the hospital or developing a heartbeat problem.

Scientists have raised serious questions about the database used for that study, and its authors have launched an independent audit.

That work had a big impact: the World Health Organization suspended use of hydroxychloroquine in a study it is leading, and French officials stopped the drug's use in hospitals. On Wednesday, the WHO said experts who reviewed safety information decided that its study could resume.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
March 4,2020

Beijing/Zurich, Mar 4: China has approved the use of Swiss drugmaker Roche's anti-inflammation drug Actemra for patients who develop severe complications from the coronavirus as it urgently hunts for new ways to combat the deadly infection that is spreading worldwide.

China is hoping that some older drugs could stop severe cytokine release syndrome (CRS), or cytokine storms, an overreaction of the immune system which is considered a major factor behind catastrophic organ failure and death in some coronavirus patients.

Actemra, a biologic drug approved in 2010 in the United States for rheumatoid arthritis (RA), inhibits high Interleukin 6 (IL-6) protein levels that drive some inflammatory diseases.

China's National Health Commission said in treatment guidelines published online on Wednesday that Actemra can now be used to treat coronavirus patients with serious lung damage and high IL-6 levels.

Separately, researchers in the country are testing Actemra, known generically as tocilizumab, in a clinical trial expected to include 188 coronavirus patients and running until May 10.

Roche, which donated 14 million yuan ($2.02 million) worth of Actemra during February, said the trial was initiated independently by a third party with the aim of exploring the efficacy and safety of the drug in coronavirus patients with CRS.

It added that there was currently no published clinical trial data on the drug's safety or efficacy against the virus.

More than 3,000 people have died and 93,000 have been infected by the novel coronavirus thought to have originated in Wuhan, China, before spreading to around 90 countries including the United States, Italy, Switzerland, France and Germany.

The Swiss company, for which China is its No. 2 market behind the United States, also makes diagnostic gear to detect the coronavirus.

Since Actemra's approval a decade ago, it has become a go-to drug against other inflammatory conditions, including cytokine storms in cancer patients receiving cell therapies from Novartis and Gilead Sciences.

In 2012 it helped save the life of a young U.S. girl, the first child to be treated for leukaemia with Novatis' Kymriah, from a post-treatment rush of IL-6.

Priced at between $20-30,000 annually for RA according to SSR Health, Roche's medicine is also used for rare juvenile arthritis and giant cell arteritis, or inflammation of the blood vessels.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Agencies
February 4,2020

The death toll in China's coronavirus rose sharply to 425 with 64 deaths on Monday alone while 3,235 new confirmed cases were reported, taking the number of those infected with the deadly disease to 20,438, Chinese health authorities said on Tuesday.

The 64 people who died on Monday were all from the Hubei province, the epicentre of the virus, China's National Health Commission said.

Also, 3,235 new confirmed cases of novel coronavirus infection were reported, a big increase in a day.

Another 5,072 new suspected cases were reported on Monday, said the commission, adding that 492 patients became seriously ill.

The commission said that 2,788 patients remained in severe condition and 23,214 people were suspected of being infected with the virus, a pointer that it is increasingly turning virulent.

The overall confirmed cases on the Chinese mainland had reached 20,438 by the end of Monday, the commission said, noting that a total of 425 people had died of the disease.

A total of 632 people had been discharged from hospital after recovery, state-run Xinhua news agency reported As the virus spreads from human to human, 221,015 close contacts had been traced, with 171,329 others still under medical observation.

By the end of Monday, 15 confirmed cases had been reported in Hong Kong, eight in the Macao and 10 in Taiwan.

The Philippines reported the first overseas death from the virus on Sunday while 148 cases have been reported from abroad.

India has reported three cases of the coronavirus. All the three patients from Kerala recently returned from the affected Wuhan city.

Currently, 647 Indians and seven Maldivians who have been evacuated from Wuhan and Hubei are in 14-day quarantine at a medical camp in Manesar, near Delhi.

As the virus continued to spread at an alarming rate, Chinese President Xi Jinping on Monday warned officials of punishment if they shirked responsibility in tackling the virus outbreak.

On Monday, China has opened a 1,000-bed hospital built in record nine days in Wuhan city and started trials for new drug to contain the virus and is set to open another 1,300 bed hospital next to it on Wednesday.

The ruling Communist Party of China on Monday held its political bureau meeting presided by President Xi to review the steps being taken on various fronts to halt the spread of the deadly virus.

The outcome of the epidemic prevention and control directly affects people's lives and health, the overall economic and social stability and the country's opening-up, Xi said.

"Those who disobey the unified command or shirk off responsibilities will be punished," Xi was quoted as saying by the state-run Xinhua news agency.

Xi said that the party and government leaders supervising them would also be held accountable in severe cases.

Chinese armament firms, including those building aircraft carrier and military aircraft, have postponed planned work in order to concentrate on controlling the risk of coronavirus, state-run Global Times reported.

Noted Chinese health expert Zhong Nanshan has said that based on the fresh evidence, the novel coronavirus, which is spreading rapidly in China and the world, may reach its peak in the next 10 to 14 days, contrary to earlier estimates of climaxing sooner.

This means that the cases would drastically increase in the next two weeks before slowing down.

Also, China has begun clinical trials to test a drug to treat the patients of the coronavirus which till now has no cure.

Currently, patients are being treated with a combination of antivirals and other measures, as scientists race to find a vaccine.

Some reports said drugs to treat HIV too was being tried to treat the patients.

The experimental antiviral drug, Remdesivir, to be tested in field trials is developed by US-based Gilead Sciences. It is aimed at treating infectious diseases such as Ebola and SARS, South China Morning Post reported.

It was given to the first US patient last week - a 35-year-old man whose condition appeared to improve within a day, it said.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.